Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Reported Goals of Women With Urinary Incontinence in Primary Care.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Older Black and Hispanic Patient Perceptions of Medicare Annual Wellness Visits: A Qualitative Study.

Annals of family medicine·2026
Same author

Evaluating the early effects of using an online educational module to elicit patient preferences for treatment following pre-visit screening for urinary incontinence in primary care.

Family practice·2026
Same author

Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease.

American journal of hematology·2026
Same author

Changing Clinician Behavior in Geriatrics: Point-of-Care Alerts for Prostate-Specific Antigen Screening.

American journal of preventive medicine·2026
Same author

Automated Screening and Education for Women With Urinary Incontinence in Primary Care.

JAMA internal medicine·2026

Related Experiment Video

Updated: Sep 11, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.4K

BCOR, BCORL1, and BCL6 Mutations in Pediatric Leukemias.

Thomas C Fisher-Heath1, Aastha Sharma1, Mark S Marshall1

  • 1Department of Pediatrics, Indiana University School of Medicine, Riley Children's Health Indiana University Health, Indianapolis, IN 46202, USA.

Cancers
|August 14, 2025
PubMed
Summary
This summary is machine-generated.

Rare mutations in B-cell lymphoma-6 corepressor (BCOR) and BCOR-like 1 (BCORL1) were identified in pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Further research is needed to understand their role in these pediatric myeloid malignancies.

Keywords:
BCL6BCORBCORL1acute myeloid leukemiamyelodysplastic syndrome

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K

Related Experiment Videos

Last Updated: Sep 11, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.4K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Somatic and epigenetic alterations are crucial in myeloid leukemogenesis.
  • These alterations impact risk stratification and treatment strategies for myeloid malignancies.
  • The role of rare mutations, such as BCOR and BCORL1, in pediatric myeloid cancers is not well understood.

Purpose of the Study:

  • To investigate the significance of BCOR and BCORL1 mutations in pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Main Methods:

  • A case series approach was used.
  • The study focused on pediatric and adolescent patients with de novo AML harboring BCOR/BCORL1 mutations.

Main Results:

  • The study identified BCOR/BCORL1 mutations in a series of pediatric and adolescent patients with de novo AML.
  • This case series highlights the presence of these rare mutations in the studied pediatric population.

Conclusions:

  • The findings suggest that BCOR/BCORL1 mutations occur in pediatric AML.
  • Larger cohort studies are necessary to fully elucidate the role and clinical implications of BCOR/BCORL1 mutations in pediatric AML and MDS.